Incidence of chemotherapy-induced amenorrhea associated with epirubicin, docetaxel and navelbine in younger breast cancer patients

BMC Cancer

Research Article

Hong Yin¹  Jing-Jing Ma¹  Shui Wang²  Ling Chen²  Li-Jun Ling²  Wen-Bin Zhou²  Ai-di Tao²  Xiao-An Liu²  Xiao-Ming Zha²  Lin Chen²  Jun-Cheng Dai³ 

[1] Department of Breast Surgery, Nanjing Maternity and Child Health Care Hospital of Nanjing Medical University, Nanjing, P.R. China;Department of Breast Surgery, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, 210029, Nanjing, P.R. China;Department of Epidemiology and Biostatistics, Nanjing Medical University School of Public Health, 140 Hanzhong Road, 210029, Nanjing, P.R. China;

关键词: Breast Cancer;    Tamoxifen;    Docetaxel;    Adjuvant Chemotherapy;    Epirubicin;   

DOI  :  10.1186/1471-2407-10-281

 received in 2010-01-06, accepted in 2010-06-11,  发布年份 2010

来源: Springer

【 摘 要 】

BackgroundThe rates of chemotherapy-induced amenorrhea (CIA) associated with docetaxel-based regimens reported by previous studies are discordant. For navelbine-based chemotherapies, rates of CIA have seldom been reported.MethodsOf 170 premenopausal patients recruited between January 2003 and September 2008, 78 were treated with fluorouracil plus epirubicin and cyclophosphamide (FEC), 66 were treated with docetaxel plus epirubicin (TE), and 26 were treated with navelbine plus epirubicin (NE). Patient follow-up was carried up every 3-4 months during the first year, then every 9-12 months during subsequent years.ResultsIn univariate analysis, the rates of CIA were 44.87% for the FEC regimen, 30.30% for the TE regimen and 23.08% for the NE regimen (P = 0.068). Significant differences in the rates of CIA were not found between the FEC and TE treatment groups (P > 0.05), but were found between the FEC and NE treatment groups (P < 0.05). Furthermore, no significant differences were found between the TE and NE regimens (P > 0.05). Tamoxifen use was a significant predictor for CIA (P = 0.001), and age was also a significant predictor (P < 0.001). In multivariate analysis, age (P < 0.001), the type of chemotherapy regimens (P = 0.009) and tamoxifen use (P = 0.003) were all significant predictors.ConclusionsAge and administration of tamoxifen were found to be significant predictive factors of CIA, whereas docetaxel and navelbine based regimens were not associated with higher rates of CIA than epirubicin-based regimen.

【 授权许可】

Unknown   
© Zhou et al; licensee BioMed Central Ltd. 2010. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.